July 2 (Reuters) - AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC Pharmaceutical Group to discover ...

Abbisko will lead the study, with both companies jointly sharing clinical trial responsibilities.

Abbisko Therapeutics has entered into a strategic collaboration agreement with AstraZeneca (AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell ...

Texas Attorney General Ken Paxton announced Monday that his office has reached a settlement with AstraZeneca Pharmaceuticals ...

AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

AstraZeneca has impressed oncology patient groups, rising to second place on PatientView’s corporate reputation ranking on the back of strength in breast and lung cancer. | AstraZeneca has impressed ...

AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induce providers to ...

AstraZeneca ( (GB:AZN)) has issued an announcement. AstraZeneca has admitted 14,784 additional ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market, bringing its total ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research process.

AstraZeneca (LSE:AZN) is back in focus after a recent pullback, with the stock down about 5% over the past month and over the past 3 months, prompting investors to reassess its current valuation. See ...

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a ...

AstraZeneca agreed to pay $34 million to settle claims that the company paid kickbacks to improperly influence prescriptions ...